Valuation: Marker Therapeutics, Inc.

Market Cap 21.34M 18.71M 17.29M 15.9M 30.01M 2.06B 30.49M 207M 81.05M 1.01B 80.14M 78.39M 3.47B P/E 2026 *
-1.33x
P/E 2027 * -1.26x
Enterprise Value 21.34M 18.71M 17.29M 15.9M 30.01M 2.06B 30.49M 207M 81.05M 1.01B 80.14M 78.39M 3.47B EV / Sales 2026 *
7.54x
EV / Sales 2027 * 1.06x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Marker Therapeutics, Inc.

1 day-2.29%
1 week-12.33%
Current month-12.93%
1 month-3.76%
3 months-23.35%
6 months-39.62%
Current year-14.09%
1 week 1.28
Extreme 1.28
1.44
1 month 1.28
Extreme 1.28
1.72
Current year 1.17
Extreme 1.17
2.46
1 year 0.81
Extreme 0.8099
2.46
3 years 0.81
Extreme 0.8099
9.68
5 years 0.67
Extreme 0.6706
23.52
10 years 0.67
Extreme 0.6706
135.5
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Date Insider Type Main position Quantity % Market Cap.
11/17/25 Free

Director

221,741 1.7138%
11/17/25 Free

Chairman

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-12.33%-24.71%-78.67% 21.84M
-0.49%-4.01%-0.84%+2.28% 49.18B
-3.10%-1.94%+370.99%+572.60% 39.58B
-0.46%+2.18%+5.44%+61.01% 34.69B
-1.14%-1.76%+26.94%-9.93% 34.42B
-1.82%-1.43%+0.52%+31.85% 27.11B
-3.54%-5.08% - - 16.21B
-1.82%-0.43%+69.28%+113.82% 15.36B
+1.17%+2.30%+15.87%+18.26% 14.05B
-2.25%+0.05%+15.77%-32.83% 13.02B
Average -1.57%-2.00%+53.25%+75.38% 24.36B
Weighted average by Cap. -1.43%-1.02%+75.90%+118.66%

Financials

2026 *2027 *
Net sales 2.83M 2.48M 2.29M 2.11M 3.98M 273M 4.04M 27.42M 10.75M 134M 10.63M 10.4M 460M 20.09M 17.61M 16.27M 14.97M 28.24M 1.94B 28.69M 195M 76.28M 948M 75.42M 73.78M 3.27B
Net income -19.36M -16.97M -15.69M -14.43M -27.22M -1.87B -27.66M -188M -73.53M -914M -72.7M -71.12M -3.15B -19.89M -17.44M -16.12M -14.82M -27.97M -1.92B -28.42M -193M -75.54M -939M -74.69M -73.06M -3.23B
Net Debt - -
Logo Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
5
Date Price Change Volume
26-07-20 US$1.280 -2.29% 58,384
26-07-17 US$1.310 -2.24% 30,877
26-07-16 US$1.340 -4.96% 69,078
26-07-15 US$1.410 -2.08% 19,650
26-07-14 US$1.440 -1.37% 21,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.280USD
Average target price
7.867USD
Spread / Average Target
+514.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRKR Stock